Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
8.14
+0.05 (0.62%)
Apr 17, 2026, 2:00 PM CST

Merdury Biopharmaceutical Ratios and Metrics

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3,4273,4735,4987,7784,006-
Market Cap Growth
-49.54%-36.83%-29.32%94.15%--
Enterprise Value
3,3033,3215,2757,4653,937-
Last Close Price
8.198.3013.0518.709.87-
PS Ratio
--1107.827530.001494.92-
PB Ratio
15.6015.8118.9420.0322.22-
P/TBV Ratio
16.0016.2119.2420.1722.28-
EV/Sales Ratio
--1062.907226.331469.06-
Debt / Equity Ratio
0.180.180.160.110.240.19
Net Debt / Equity Ratio
-0.56-0.56-0.63-0.74-0.54-0.05
Net Debt / EBITDA Ratio
2.182.183.936.893.340.12
Net Debt / FCF Ratio
2.152.154.105.211.030.05
Asset Turnover
--0.010.000.02-
Quick Ratio
8.338.3312.0340.8919.791.50
Current Ratio
8.848.8412.6342.2120.152.30
Return on Equity (ROE)
-26.37%-26.37%-14.90%-15.41%-32.76%-103.62%
Return on Assets (ROA)
-13.57%-13.57%-8.54%-8.55%-15.87%-49.15%
Return on Capital Employed (ROCE)
-26.50%-26.50%-16.20%-10.60%-13.90%-45.40%
Earnings Yield
-1.96%-1.94%-0.92%-0.56%-0.78%-
FCF Yield
-1.68%-1.66%-0.81%-0.71%-2.35%-
Buyback Yield / Dilution
0.29%0.29%-5.79%-5.83%-36.09%-165.94%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.